NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...

Indaptus Therapeutics (INDP) provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of ...

New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumorsNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

SUNNYVALE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Real-Time Innovations (RTI), the infrastructure software company for smart-world systems, will exhibit at Aerospace TechWeek 2025, held April 2-3 ...

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 Pharmacodynamic immune activation biomarker and pharmacokinetics ...

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 Pharmacodynamic immune activation biomarker and pharmacokinetics ...

Indaptus Therapeutics announced significant progress in its Phase 1 trial of Decoy20, with over 20 patients enrolled in the weekly dosing cohort. Initial clinical data shows promising ...

Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, “We continue to make significant progress in our Phase 1 trial of Decoy20, and enrolling more than 20 patients in the weekly dosing ...